Login to Your Account

Talecris: Fee Proposal Not the Way to Build Biosimilar Path

By Mari Serebrov

Friday, June 10, 2011
WASHINGTON – The FDA is putting the cart before the horse, Talecris Biotherapeutics Inc. said in a comment on the agency's proposed biosimilar fee structure.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription